Skip to content
Learn More

Resources

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

December 1, 2020

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using …

Read More

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

November 24, 2020

– Methods for Production in iBio’s FastPharming® System Foundational to Antifibrotic Development Program – BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled “Materials and Methods …

Read More

iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer

November 3, 2020

– Brings >20 Years of Global Biotech Operations and Business Development Experience – BRYAN, Texas, Nov. 03, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer (“COO”), effective December 1, 2020. Mr. Maddux has …

Read More

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

October 2, 2020

– Project Focused on Proteins used in the Production of Blood Cells – NEW YORK, Oct. 02, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has entered into a Master Services Agreement (“MSA”) with Boston-based Safi Biosolutions, Inc. (“Safi”) …

Read More

iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201

September 9, 2020

– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies – – iBio Plans to Continue Development of IBIO-200, its Virus-Like Particle Platform – NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has selected IBIO-201, its LicKM™-Subunit …

Read More
Top